Table 1_Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the FDA adverse event reporting system.xlsx

Table 1_Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the FDA adverse event reporting system.xlsx

Background<p>Alzheimer’s disease (AD) has a growing global prevalence, and the need for safe and effective treatments is urgent. Donepezil is commonly used therapeutic agents for AD but has safety controversies. The objective of this study was to thoroughly evaluate donepezil’s adverse event p...

Full description

Saved in:

Bibliographic Details
Main Author:	Shuo Li (143148) (author)
Other Authors:	Wenlong Qian (22608053) (author), Zhuo Zhang (72795) (author), Yonghua Chen (602708) (author), Xiaoxiao Hou (18584988) (author), Bingjie Min (22608059) (author), Hui Zhou (13228) (author), Xinyu Zhu (579718) (author), Jia Ling (12716231) (author), Wenming Yang (4017086) (author), Shijian Cao (9573488) (author)
Published:	2025
Subjects:	Neurology and Neuromuscular Diseases donepezil FDA adverse event reporting system disproportionality analyses pharmacovigilance adverse event
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Table 3_Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the FDA adverse event reporting system.xlsx
by: Shuo Li (143148)
Published: (2025)

Table 4_Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the FDA adverse event reporting system.xlsx
by: Shuo Li (143148)
Published: (2025)

Table 2_Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the FDA adverse event reporting system.xlsx
by: Shuo Li (143148)
Published: (2025)

Supplementary file 1_A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod.docx
by: Yingxiu Wu (22597094)
Published: (2025)

Metoprolol adverse events and literature analyses: case/non-case analyses using the FDA Adverse Event Reporting System (FAERS)
by: Yikuan Du (16324215)
Published: (2024)

Table 2_Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.xlsx
by: Yanjun Lu (482204)
Published: (2024)

Table 1_Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.xlsx
by: Yanjun Lu (482204)
Published: (2024)

Table 1_A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib.docx
by: Yi Yin (448434)
Published: (2024)

Table 2_A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib.xlsx
by: Yi Yin (448434)
Published: (2024)

Table 3_A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib.xlsx
by: Yi Yin (448434)
Published: (2024)

Table 2_Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database.docx
by: Yang Rui (20950656)
Published: (2025)

Table 1_Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database.docx
by: Yang Rui (20950656)
Published: (2025)

Table 3_Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database.docx
by: Yang Rui (20950656)
Published: (2025)

Table1_Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004–2023).docx
by: Xiao-Dong Chen (723918)
Published: (2024)

Table 1_A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database.xlsx
by: Ya-Jun Zhang (1625761)
Published: (2024)

Table 2_A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database.xlsx
by: Ya-Jun Zhang (1625761)
Published: (2024)

Table 1_Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system.xlsx
by: Wensheng Liu (205723)
Published: (2025)

Table 2_Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system.xlsx
by: Wensheng Liu (205723)
Published: (2025)

Table 4_Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system.xlsx
by: Wensheng Liu (205723)
Published: (2025)

Table 3_Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system.xlsx
by: Wensheng Liu (205723)
Published: (2025)

Data Sheet 1_Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system.docx
by: Qian Yu (127062)
Published: (2025)

Table 3_Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.pdf
by: Yanjun Lu (482204)
Published: (2024)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) for gemcitabine
by: Cheng Zhang (70708)
Published: (2024)

Table 1_Exploring the top 30 drugs associated with drug-induced thrombotic microangiopathy based on the FDA adverse event reporting system.docx
by: Yi Yin (448434)
Published: (2025)

Data and Code for DI-ALH Analysis Using FAERS
by: Wangyu Ye (20434733)
Published: (2024)

Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database
by: Lingling Wang (66269)
Published: (2025)

Table 3_Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system.xlsx
by: Liangxia Li (17664248)
Published: (2025)

Table 2_Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system.xlsx
by: Liangxia Li (17664248)
Published: (2025)

Data Sheet 1_Drug-induced dermatomyositis: a pharmacovigilance study of the FDA adverse event reporting system.xlsx
by: Jianing Bi (11573014)
Published: (2025)

Data Sheet 1_Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database.docx
by: Ye Hu (71531)
Published: (2025)

Supplementary file 1_Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System.doc
by: Shenglan Shang (12208562)
Published: (2025)

Signal detection and analysis of sulfasalazine adverse reaction events based on the US FDA adverse event reporting database
by: Yikuan Du (16324215)
Published: (2024)

Table 1_The real-world safety profile of ranolazine: pharmacovigilance analysis of the FAERS database.docx
by: Zujun Wen (22589756)
Published: (2025)

Drug-induced skin ulcer: real-world pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qiubai Jin (14763784)
Published: (2025)

Data Sheet 1_Psychiatric safety associated with hormone replacement therapy for menopausal symptoms: a real-world study of the FDA adverse event reporting system.zip
by: Nan Chen (142925)
Published: (2025)

Post-marketing safety associated with sodium zirconium cyclosilicate: a pharmacovigilance study based on the FDA reporting system
by: Jiankang Chen (20950641)
Published: (2025)

A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine
by: Cheng Zhong (573294)
Published: (2024)

Table 2_Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system.xlsx
by: Hao Liu (12832)
Published: (2025)

Table 1_Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system.pdf
by: Sentai Wang (20963168)
Published: (2025)

Table 1_Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database.docx
by: Yuan-Yuan Wu (5269484)
Published: (2025)

Cannot write session to /tmp/vufind_sessions/sess_dpemplf9fk6b3a5f607iv434sm